Methods for identifying long-term adverse effects of treatment in patients with eye diseases

The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

John H. Kempen, Ebenezer Daniel, Sapna Gangaputra, Kurt Dreger, Douglas A. Jabs, R. Oktay Kaçmaz, Siddharth S. Pujari, Fahd Anzaar, C. Stephen Foster, Kathy J. Helzlsouer, Grace A. Levy-Clarke, Robert B. Nussenblatt, Teresa Liesegang, James (Jim) Rosenbaum, Eric Suhler

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Methods: Advantages and disadvantages of potential study designs for evaluating rare, late-occurring events are reviewed, and the SITE Cohort Study approach is presented. Results: The randomized, controlled trial is the most robust method for evaluating treatment effects, but long study duration, high costs, and ethical concerns when studying toxicity limit its use in this setting. Retrospective cohort studies are potentially more cost-effective and timely, if records exist providing the desired information over sufficient follow-up time in the past. Case-control methods require extremely large sample sizes to evaluate risk associated with rare exposures, and recall bias is problematic when studying mortality. The SITE Cohort Study is a retrospective cohort study. Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of ∼9,250 ocular inflammation patients at five tertiary centers over up to 30 years. Mortality and cause-specific mortality outcomes over ∼100,000 person-years are ascertained using the National Death Index. Immunosuppressed and non-immunosuppressed groups of patients are compared with each other and general population mortality rates from US vital statistics. Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents. Conclusions: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer. This epidemiologic approach may be useful for evaluating long-term risks of systemic therapies for other ocular diseases.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalOphthalmic Epidemiology
Volume15
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Eye Diseases
Immunosuppressive Agents
Cohort Studies
Mortality
Antimetabolites
Alkylating Agents
Therapeutics
Retrospective Studies
Inflammation
Epidemiologic Methods
T-Lymphocytes
Costs and Cost Analysis
Neoplasms
Vital Statistics
Long Term Adverse Effects
Sample Size
Immunosuppression
Population
Medical Records
Randomized Controlled Trials

Keywords

  • Cancer
  • Cohort study
  • Immunosuppression
  • Mortality
  • Ocular inflammation

ASJC Scopus subject areas

  • Ophthalmology
  • Epidemiology

Cite this

Methods for identifying long-term adverse effects of treatment in patients with eye diseases : The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. / Kempen, John H.; Daniel, Ebenezer; Gangaputra, Sapna; Dreger, Kurt; Jabs, Douglas A.; Kaçmaz, R. Oktay; Pujari, Siddharth S.; Anzaar, Fahd; Foster, C. Stephen; Helzlsouer, Kathy J.; Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Liesegang, Teresa; Rosenbaum, James (Jim); Suhler, Eric.

In: Ophthalmic Epidemiology, Vol. 15, No. 1, 01.2008, p. 47-55.

Research output: Contribution to journalArticle

Kempen, JH, Daniel, E, Gangaputra, S, Dreger, K, Jabs, DA, Kaçmaz, RO, Pujari, SS, Anzaar, F, Foster, CS, Helzlsouer, KJ, Levy-Clarke, GA, Nussenblatt, RB, Liesegang, T, Rosenbaum, JJ & Suhler, E 2008, 'Methods for identifying long-term adverse effects of treatment in patients with eye diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study', Ophthalmic Epidemiology, vol. 15, no. 1, pp. 47-55. https://doi.org/10.1080/09286580701585892
Kempen, John H. ; Daniel, Ebenezer ; Gangaputra, Sapna ; Dreger, Kurt ; Jabs, Douglas A. ; Kaçmaz, R. Oktay ; Pujari, Siddharth S. ; Anzaar, Fahd ; Foster, C. Stephen ; Helzlsouer, Kathy J. ; Levy-Clarke, Grace A. ; Nussenblatt, Robert B. ; Liesegang, Teresa ; Rosenbaum, James (Jim) ; Suhler, Eric. / Methods for identifying long-term adverse effects of treatment in patients with eye diseases : The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. In: Ophthalmic Epidemiology. 2008 ; Vol. 15, No. 1. pp. 47-55.
@article{e824f910bfc040369ca5124de2497e7a,
title = "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study",
abstract = "Purpose: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Methods: Advantages and disadvantages of potential study designs for evaluating rare, late-occurring events are reviewed, and the SITE Cohort Study approach is presented. Results: The randomized, controlled trial is the most robust method for evaluating treatment effects, but long study duration, high costs, and ethical concerns when studying toxicity limit its use in this setting. Retrospective cohort studies are potentially more cost-effective and timely, if records exist providing the desired information over sufficient follow-up time in the past. Case-control methods require extremely large sample sizes to evaluate risk associated with rare exposures, and recall bias is problematic when studying mortality. The SITE Cohort Study is a retrospective cohort study. Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of ∼9,250 ocular inflammation patients at five tertiary centers over up to 30 years. Mortality and cause-specific mortality outcomes over ∼100,000 person-years are ascertained using the National Death Index. Immunosuppressed and non-immunosuppressed groups of patients are compared with each other and general population mortality rates from US vital statistics. Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22{\%}/49{\%} for antimetabolites, 28{\%}/62{\%} for T-cell inhibitors, and 36{\%}/81{\%} for alkylating agents. Conclusions: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer. This epidemiologic approach may be useful for evaluating long-term risks of systemic therapies for other ocular diseases.",
keywords = "Cancer, Cohort study, Immunosuppression, Mortality, Ocular inflammation",
author = "Kempen, {John H.} and Ebenezer Daniel and Sapna Gangaputra and Kurt Dreger and Jabs, {Douglas A.} and Ka{\cc}maz, {R. Oktay} and Pujari, {Siddharth S.} and Fahd Anzaar and Foster, {C. Stephen} and Helzlsouer, {Kathy J.} and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Teresa Liesegang and Rosenbaum, {James (Jim)} and Eric Suhler",
year = "2008",
month = "1",
doi = "10.1080/09286580701585892",
language = "English (US)",
volume = "15",
pages = "47--55",
journal = "Ophthalmic Epidemiology",
issn = "0928-6586",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Methods for identifying long-term adverse effects of treatment in patients with eye diseases

T2 - The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

AU - Kempen, John H.

AU - Daniel, Ebenezer

AU - Gangaputra, Sapna

AU - Dreger, Kurt

AU - Jabs, Douglas A.

AU - Kaçmaz, R. Oktay

AU - Pujari, Siddharth S.

AU - Anzaar, Fahd

AU - Foster, C. Stephen

AU - Helzlsouer, Kathy J.

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Liesegang, Teresa

AU - Rosenbaum, James (Jim)

AU - Suhler, Eric

PY - 2008/1

Y1 - 2008/1

N2 - Purpose: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Methods: Advantages and disadvantages of potential study designs for evaluating rare, late-occurring events are reviewed, and the SITE Cohort Study approach is presented. Results: The randomized, controlled trial is the most robust method for evaluating treatment effects, but long study duration, high costs, and ethical concerns when studying toxicity limit its use in this setting. Retrospective cohort studies are potentially more cost-effective and timely, if records exist providing the desired information over sufficient follow-up time in the past. Case-control methods require extremely large sample sizes to evaluate risk associated with rare exposures, and recall bias is problematic when studying mortality. The SITE Cohort Study is a retrospective cohort study. Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of ∼9,250 ocular inflammation patients at five tertiary centers over up to 30 years. Mortality and cause-specific mortality outcomes over ∼100,000 person-years are ascertained using the National Death Index. Immunosuppressed and non-immunosuppressed groups of patients are compared with each other and general population mortality rates from US vital statistics. Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents. Conclusions: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer. This epidemiologic approach may be useful for evaluating long-term risks of systemic therapies for other ocular diseases.

AB - Purpose: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Methods: Advantages and disadvantages of potential study designs for evaluating rare, late-occurring events are reviewed, and the SITE Cohort Study approach is presented. Results: The randomized, controlled trial is the most robust method for evaluating treatment effects, but long study duration, high costs, and ethical concerns when studying toxicity limit its use in this setting. Retrospective cohort studies are potentially more cost-effective and timely, if records exist providing the desired information over sufficient follow-up time in the past. Case-control methods require extremely large sample sizes to evaluate risk associated with rare exposures, and recall bias is problematic when studying mortality. The SITE Cohort Study is a retrospective cohort study. Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of ∼9,250 ocular inflammation patients at five tertiary centers over up to 30 years. Mortality and cause-specific mortality outcomes over ∼100,000 person-years are ascertained using the National Death Index. Immunosuppressed and non-immunosuppressed groups of patients are compared with each other and general population mortality rates from US vital statistics. Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents. Conclusions: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer. This epidemiologic approach may be useful for evaluating long-term risks of systemic therapies for other ocular diseases.

KW - Cancer

KW - Cohort study

KW - Immunosuppression

KW - Mortality

KW - Ocular inflammation

UR - http://www.scopus.com/inward/record.url?scp=39749198170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749198170&partnerID=8YFLogxK

U2 - 10.1080/09286580701585892

DO - 10.1080/09286580701585892

M3 - Article

VL - 15

SP - 47

EP - 55

JO - Ophthalmic Epidemiology

JF - Ophthalmic Epidemiology

SN - 0928-6586

IS - 1

ER -